-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-102 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-102 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-102 in Gastric Cancer Drug Details: FS-102 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-102 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-102 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-102 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-102 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-102 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-102 in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Empasiprubart in Delayed Graft Function (DGF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Empasiprubart in Delayed Graft Function (DGF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Empasiprubart in Delayed Graft Function (DGF) Drug Details: ARGX-117 (PRO-02)...
-
Product Insights
NewNet Present Value Model: Inhibrx Inc’s INBRX-101
Empower your strategies with our Net Present Value Model: Inhibrx Inc's INBRX-101 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence. emphysema. The therapeutic candidate comprises of alpha-1 antitrypsin (AAT)-Fc fusion proteins and developed based...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Head And Neck Squamous Cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ziv-aflibercept in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ziv-aflibercept in Metastatic Uveal Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ziv-aflibercept in Metastatic Uveal Melanoma Drug Details: Ziv-aflibercept (Zaltrap / Aflitiv...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Gallbladder Cancer Drug Details: Margetuximab (Margenza) is a Fc-engineered human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Gastric Cancer Drug Details: Margetuximab (Margenza) is a Fc-engineered human...